ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Coronavirus

AstraZeneca starts coronavirus vaccine trials in Japan

Drugmaker says it will deliver 30m doses to the country by next March

AstraZeneca has signed an agreement with the Japanese government to supply the country with 120 million doses of a COVID-19 vaccine.   © Reuters

TOKYO -- AstraZeneca has begun clinical trials for a coronavirus vaccine candidate in Japan, its local unit announced Friday.

The U.K.-headquartered company is the third to start such trials in the country, after AnGes, a drugmaker that was founded at Osaka University, and U.S.-based Johnson & Johnson. If successful, it could become one of the top suppliers for coronavirus vaccines in Japan.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more